Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study
The study investigates the role of IMP3 as a prognostic marker in colorectal carcinoma (CRC), a significant health concern in Egypt with a notable male predominance. The findings could position IMP3 as a valuable biomarker for CRC, potentially leading to the development of targeted therapies or diagnostic tools. Given the high incidence of CRC in developing countries, there is a substantial market opportunity for products that enhance early detection and treatment outcomes. Competitive analysis should consider existing biomarkers and therapeutic agents targeting similar pathways. Diligence should focus on the regulatory landscape for biomarkers in oncology and potential collaborations with local healthcare providers.
Indication: Colorectal Cancer
Modality: RNA therapy
Target: Insulin-like growth factor II m-RNA-binding protein 3 (IMP3)
Sponsor: Sohag University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Insulin-like growth factor II m-RNA-binding protein 3 (IMP3)
View original source fields
Condition raw: Colorectal Cancer
Condition normalized: Colorectal Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Insulin-like growth factor II m-RNA-binding protein 3 (IMP3)
Target normalized: Insulin-like growth factor II m-RNA-binding protein 3 (IMP3)